RevolKa Ltd., a Sendai, Japan-based biotech company providing an AI-driven protein engineering technology platform called aiProtein, raised US$1.4M in Series A extension funding.
The round was co-led by existing investors D3 LLC and TOHOKU University Venture Partners Co., Ltd., with participation from DEEPCORE Inc.
The company intends to use the funds to advance its drug discovery programs for rare diseases and support collaborative partnering efforts.
RevolKa provides the proprietary aiProtein platform, which develops an AI-assisted protein engineering solution. Proteins are linear polymers composed of amino acids and their derivatives, folding into a tertiary structure through internal complex atomic interactions to exhibit biological functions. The relationship between protein sequence, structure, and function remains poorly understood, limiting rational design of protein. Its AI engine is trained on sequence-to-function relationship data, enabling the efficient generation of sequences of proteins with desired functions. Furthermore, aiProtein can simultaneously engineer multiple properties, offering a solution for creating new functional proteins suitable for pharmaceutical and industrial applications.
FinSMEs
20/05/2025